Overview

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Status:
Not yet recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Aulos Bioscience, Inc.

Treatments:

Aldesleukin